TY - JOUR
T1 - N-acetylcysteine amide (NACA) prevents retinal degeneration by up-regulating reduced glutathione production and reversing lipid peroxidation
AU - Schimel, Andrew M.
AU - Abraham, Linu
AU - Cox, Douglas
AU - Sene, Abdoulaye
AU - Kraus, Courtney
AU - Dace, Dru S.
AU - Ercal, Nuran
AU - Apte, Rajendra S.
N1 - Funding Information:
Supported by NIH grants K08EY016139 and R01EY019287 (R.S.A.), NIH Vision core grant P30 EY 02687 , a Carl Marshall Reeves and Mildred Almen Reeves Foundation Inc. Award (R.S.A.), a Research to Prevent Blindness Inc. Career Development Award (R.S.A.), the International Retina Research Foundation (R.S.A.), an American Federation for Aging Research grant (R.S.A.), the American Retina Foundation (R.S.A.), an International Retinal Research Foundation Callahan Award (D.S.D.), a Lacey Foundation Research Award (A.S.), NIH and National Institute on Drug Abuse award R15DA023409 (N.E.), and a Research to Prevent Blindness Inc. unrestricted grant to Washington University.
PY - 2011/5
Y1 - 2011/5
N2 - Oxidative stress plays a critical role in accelerating retinal pigment epithelial dysfunction and death in degenerative retinal diseases, including age-related macular degeneration. Given the key role of oxidative stress-induced retinal pigment epithelial cell death and secondary photoreceptor loss in the pathogenesis of agerelated macular degeneration, we hypothesized that a novel thiol antioxidant, N-acetylcysteine amide (NACA), might ameliorate cellular damage and subsequent loss of vision. Treatment of human retinal pigment epithelial cells with NACA protected against oxidative stress-induced cellular injury and death. NACA acted mechanistically by scavenging existing reactive oxygen species while halting production of reactive oxygen species by reversing lipid peroxidation. Furthermore, NACA functioned by increasing the levels of reduced glutathione and the phase II detoxification enzyme glutathione peroxidase. Treatment of mice exposed to phototoxic doses of light with NACA maintained retinal pigment epithelial cell integrity and prevented outer nuclear layer cell death as examined by histopathologic methods and rescued photoreceptor function as measured by electroretinography. These observations indicate that NACA protects against oxidative stress-induced retinal pigment epithelial and photoreceptor cell death in vitro and in vivo. The data suggest that NACA may be a novel treatment in rescuing retinal function and preventing vision loss secondary to retinal degenerative diseases, including age-related macular degeneration.
AB - Oxidative stress plays a critical role in accelerating retinal pigment epithelial dysfunction and death in degenerative retinal diseases, including age-related macular degeneration. Given the key role of oxidative stress-induced retinal pigment epithelial cell death and secondary photoreceptor loss in the pathogenesis of agerelated macular degeneration, we hypothesized that a novel thiol antioxidant, N-acetylcysteine amide (NACA), might ameliorate cellular damage and subsequent loss of vision. Treatment of human retinal pigment epithelial cells with NACA protected against oxidative stress-induced cellular injury and death. NACA acted mechanistically by scavenging existing reactive oxygen species while halting production of reactive oxygen species by reversing lipid peroxidation. Furthermore, NACA functioned by increasing the levels of reduced glutathione and the phase II detoxification enzyme glutathione peroxidase. Treatment of mice exposed to phototoxic doses of light with NACA maintained retinal pigment epithelial cell integrity and prevented outer nuclear layer cell death as examined by histopathologic methods and rescued photoreceptor function as measured by electroretinography. These observations indicate that NACA protects against oxidative stress-induced retinal pigment epithelial and photoreceptor cell death in vitro and in vivo. The data suggest that NACA may be a novel treatment in rescuing retinal function and preventing vision loss secondary to retinal degenerative diseases, including age-related macular degeneration.
UR - http://www.scopus.com/inward/record.url?scp=79959232837&partnerID=8YFLogxK
U2 - 10.1016/j.ajpath.2011.01.036
DO - 10.1016/j.ajpath.2011.01.036
M3 - Article
C2 - 21457933
AN - SCOPUS:79959232837
SN - 0002-9440
VL - 178
SP - 2032
EP - 2043
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 5
ER -